Tanabe T, Tanaka G, Okutani T, Nishimoto K, Kawashita E, Yoneda K, Fujii M, Shiraishi T
Department of Urology, Matsuyama Red Cross Hospital, Japan.
Gan To Kagaku Ryoho. 1992 Nov;19(13):2207-11.
Chemotherapy regimens including Methotrexate, Vinblastine. Doxorubicin and Cis-platinum (M-VAC) have shown objective responses in more than 50% of uroepithelial tumors. And intra-arterial chemotherapy can theoretically increase the drug concentration delivered to the tumor with maximum efficacy and less toxicity. In this report we review our experience at Matsuyama Red Cross Hospital between September 1987 and February 1991 using intra-arterial M-VAC in 21 evaluable patients with bladder cancer. Response was observed in 62% of the treated patients, two with complete remission and eleven with partial remission. WBC nadir and platelet nadir were mild to moderate. Other adverse effects such as mucositis, hair loss and creatinine elevation were seen in a small number of patients. Intra-arterial M-VAC can be one of the most useful forms of chemotherapy for patients with bladder cancer.
包括甲氨蝶呤、长春碱、多柔比星和顺铂（M-VAC）的化疗方案已在超过50%的尿路上皮肿瘤中显示出客观反应。理论上，动脉内化疗可以提高输送到肿瘤的药物浓度，疗效最大化且毒性更小。在本报告中，我们回顾了松山红十字医院在1987年9月至1991年2月期间对21例可评估的膀胱癌患者使用动脉内M-VAC的经验。62%的治疗患者出现反应，2例完全缓解，11例部分缓解。白细胞最低点和血小板最低点为轻度至中度。少数患者出现其他不良反应，如粘膜炎、脱发和肌酐升高。动脉内M-VAC可能是膀胱癌患者最有效的化疗形式之一。
